PIEZO2 and irritable bowel syndrome: It was reported that in IBS patients, the expression of Piezo2 significantly correlated to the visceral sensitivity (Bai et al., 2017), indicating that Piezo2 was a candidate biomarker for visceral hypersensitivity in IBS.